The International Generic and Biosimilar Medicines Association (IGBA) hopes to build momentum for the use of biosimilars.
The International Generic and Biosimilar Medicines Association (IGBA) has launched the first Global Biosimilars Week, an attempt to raise awareness of the value of biosimilars and provide resources for interested persons to find out more about these lower-cost agents
The website for Global Biosimilars Week contains patient testimonials, an introductory overview of biosimilars, and various other resources designed to explain the global reach biosimilars have achieved and their importance for extending treatment options.
“Enhanced knowledge of biosimilar medicines will support improved access to life-saving biological treatments and support healthcare systems, which are under increasing pressure due to the rising costs of innovative treatments and the new fiscal demands created by the Covid-19 global public health crisis,” said Hanan Sboul, chair of the IGBA.
IGBA is based in Geneva and is a trade association of companies that develop and market biosimilar medicines, which are often sold at significant discounts to innovator biologics and help to increase access to treatment for patients.
Global Biosimilars Week will continue through Friday, November 20. “Enhanced knowledge of biosimilar medicines will support improved access to life-saving biological treatments and support health care systems, which are under increasing pressure due to the rising costs of innovative treatments and the new fiscal demands created by the Covid-19 global public health crisis,” said Erika Satterwhite, chair of the IGBA biosimilars Committee.
The group is inviting interested members of the public to join an online discussion about biosimilars on social media this week using the hashtag #GlobalBiosimilarsWeek.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Paving the Way for Equitable Biosimilar Access in Australian Dermatology Clinics
May 13th 2025Australia’s growing reliance on high-cost biologics for inflammatory skin diseases has placed significant pressure on its health system—but a new report suggests biosimilars could offer financial relief, provided uptake barriers are addressed through policy reform and education.
Switching From Avastin to Bevacizumab-bvzr in CRC, NSCLC Can Reduce Medicare Costs
May 10th 2025Monthly savings from fully converting Medicare patients with metastatic colorectal cancer (CRC) and non-squamous metastatic non-small cell lung cancer (NSCLC) from reference bevacizumab to bevacizumab-bvzr could fund 13,887 and 8,959 additional patient-months of treatment, respectively, according to a cost-effectiveness study.